Mattia D'Agostino

Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino
Country flagItaly

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (20)

Year:

2026

Year:

2026

Circulating tumor cells (CTC) represent a high-risk biomarker in newly diagnosed multiple myeloma (NDMM); however, their prognostic value among transplant-eligible (TE) patients receiving daratumumab/bortezomib/lenalidomide/dexamethasone (D-VRd) remains unknown. In this study, we analyzed CTC in the phase 3 PERSEUS/EMN017 trial. TE-NDMM patients were randomized (1:1) to D-VRd with daratumumab/lenalidomide maintenance (D-VRd group) or bortezomib/lenalidomide/dexamethasone (VRd) with lenalidomide maintenance (VRd group), both with transplant. A subset of 451 of 709 patients from PERSEUS (D-VRd, 231/355; VRd, 220/354) had screening blood samples collected for CTC analysis by flow cytometry. CTC were detected in 370 patients (82%; median limit of detection, 0.0004%). CTC were prognostic of progression-free survival (PFS), independent of other factors, as a continuous (hazard ratio [HR], 1.36 [95% confidence interval (CI), 1.15-1.60]; P< .001) and categorical variable (≥0.175% CTC-high, optimal threshold). D-VRd improved PFS vs VRd in CTC-low patients (4-year rates: 88% vs 74%; HR, 0.42 [95% CI, 0.25-0.70]; P = .0013). Regardless of study treatment, minimal residual disease (MRD)-negativity rates were lower in CTC-high vs CTC-low patients (10–5: 52.2% vs 66.2%; 10–6: 34.8% vs 52.4%). D-VRd significantly increased MRD-negativity rates vs VRd among CTC-high (10–5: 69.4% vs 33.3%; 10–6: 47.2% vs 21.2%; both P< .05) and CTC-low patients (10–5: 74.4% vs 57.8%; 10–6: 65.6% vs 38.5%; both P< .001), with similar observations for sustained MRD-negativity. CTC levels are an independent prognostic factor in TE-NDMM treated with standard-of-care frontline quadruplet. D-VRd improved and sustained MRD-negativity rates in CTC-high and CTC-low, and improved PFS for CTC-low with a positive trend in CTC-high patients. This trial was registered at www.clinicaltrials.gov as #NCT03710603.

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Multiple myeloma (MM) is a haematological malignancy characterised by high genomic heterogeneity. One of the most common cytogenic abnormalities in MM is the gain of genetic material at the long arm (q) of chromosome 1 (+ 1q). While many mechanisms of resistance have been associated with + 1q alterations (e.g. CD38 downregulation, impairment of complement-dependent cytotoxicity, or induction of immunosuppression), the precise genetic or pathogenetic factors responsible for these alterations are still being investigated. Although interphase fluorescence in situ hybridisation (iFISH) is the gold standard for the detection of + 1q abnormalities used by the majority of diagnostic laboratories worldwide, there are no universally recognised cut-offs for + 1q positivity or a threshold for clinical meaningfulness. Because iFISH alone is insufficient to elucidate the extent of + 1q and other cytogenetic abnormalities in MM, sequencing-based methods could be adopted. The second revision of the international staging system for MM recently recognised + 1q as a high-risk feature. There is increasing evidence that + 1q has a prognostic value and influences the duration of remission, suggesting that patients with MM and + 1q may benefit from tailored therapy. This review comprehensively summarises the most recent biological evidence and clinical data on + 1q abnormalities in MM. However, given the heterogeneous data available, it remains difficult to draw firm conclusions. In clinical practice, +1q alterations should be evaluated along with other cytogenetic abnormalities and other biological and clinical characteristics of the disease. Ongoing and future studies will help the full understanding of the role of + 1q in MM.

Year:

2025

Despite significant improvements in survival of patients with multiple myeloma (MM), outcomes remain heterogeneous, and a significant proportion of patients experience suboptimal outcomes. Importantly, traditional prognostic factors based on data from patients treated with older therapies no longer capture prognosis accurately in the contemporary era of novel triplet or quadruplet therapies. Therefore, risk stratification requires refinement in the context of available and investigational treatment options in routine practice and clinical trials, respectively. The current identification of high-risk MM (HRMM) in routine practice is based on the Revised International Staging System, which stratifies patients using a combination of widely available serum biomarkers and chromosomal abnormalities assessed via fluorescence in situ hybridization. In recent years, a substantial body of evidence concerning additional clinical, biological, and molecular/genomic prognostic factors has accumulated, along with new MM risk stratification tools and consensus reports. The International Myeloma Society, along with the International Myeloma Working Group, convened an Expert Panel with the primary aim of revisiting the definition of HRMM and formulating a practical and data-driven consensus definition, based on new evidence from molecular/genomic assays, updated clinical data, and contemporary risk stratification concepts. The Panel proposes the following Consensus Genomic Staging (CGS) of HRMM which relies upon the presence of at least one of these abnormalities: (1) del(17p), with a cutoff of >20% clonal fraction, and/or TP53 mutation; (2) an IgH translocation including t(4;14), t(14;16), or t(14;20) along with 1q+ and/or del(1p32); (3) monoallelic del(1p32) along with 1q+ or biallelic del(1p32); or (4) β2 microglobulin ≥5.5 mg/L with normal creatinine (<1.2 mg/dL).

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Collaborators (31)

Roberto Piva

University of Turin

ITALY
View details

David Siegel

Chief, Myeloma Division

-

UNITED STATES
View details

David Cairns

Professor of Clinical Trials Research

University of Leeds

UNITED KINGDOM
View details

Francesca Gay

Associate Professor

University of Turin

ITALY
View details

Jill Corre

-

FRANCE
View details

Brian Walker

Professor

University of Miami

UNITED STATES
View details

Vittorio Montefusco

Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo

ITALY
View details

Bronno van der Holt

Erasmus University Rotterdam

NETHERLANDS
View details

Davide Crucitti

Instituto de Investigación Sanitaria de Santiago

SPAIN
View details

Martin Kaiser

Professor of Haematology

The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust

UNITED KINGDOM
View details

Benedetto Bruno

Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino

ITALY
View details

ROBERTO MINA

Assistant professor

Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino

ITALY
View details

Gordon Cook

University of Leeds

UNITED KINGDOM
View details

K. Martin Kortüm

University Hospital Würzburg

GERMANY
View details

MICHELE CAVO

University of Bologna

ITALY
View details

Samir Parekh

Director, Center of Excellence for Multiple Myeloma

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Robert Orlowski

Florence Maude Thomas Cancer Research Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Eugenio Morelli

Assistant Professor

Università degli Studi di Torino

ITALY
View details

Mario Nuvolone

University of Pavia

ITALY
View details

Niccolò Bolli

Associate Professor

University of Milan

ITALY
View details

Mehmet Samur

Senior Research Scientist

Dana-Farber Cancer Institute

UNITED STATES
View details

Evangelos Terpos

Professor of Hematology

National and Kapodistrian University of Athens - Faculty of Medicine

GREECE
View details

ELISABETTA MEREU

University of Turin

ITALY
View details

Enrique M. Ocio

Head of the Department

Marqués de Valdecilla University Hospital

SPAIN
View details

Ramón García-Sanz

Profesor Titular de Medicina / Hematología

Universidad Complutense de Madrid

SPAIN
View details

Albert Oriol

Institut Català d'Oncologia

SPAIN
View details

Herve Avet-Loiseau

-

FRANCE
View details

Bruno David Lourenço Paiva

Clinica Universidad de Navarra

SPAIN
View details

Juan-José Garcés

Research Scholar

Sloan Kettering Institute

UNITED STATES
View details

Norma C. Gutiérrez

-

SPAIN
View details

Marc S. Raab

University Hospital Heidelberg

GERMANY
View details